ACER THERAPEUTICS INC., 10-Q filed on 11/13/2017
Quarterly Report
Document and Entity Information
9 Months Ended
Sep. 30, 2017
Nov. 1, 2017
Document And Entity Information [Abstract]
 
 
Entity Registrant Name
Acer Therapeutics Inc. 
 
Entity Central Index Key
0001069308 
 
Document Type
10-Q 
 
Document Period End Date
Sep. 30, 2017 
 
Amendment Flag
false 
 
Current Fiscal Year End Date
--12-31 
 
Is Entity a Well-known Seasoned Issuer?
No 
 
Is Entity a Voluntary Filer?
No 
 
Is Entity's Reporting Status Current?
Yes 
 
Entity Filer Category
Smaller Reporting Company 
 
Entity Common Stock, Shares Outstanding
 
6,450,766 
Document Fiscal Period Focus
Q3 
 
Document Fiscal Year Focus
2017 
 
Consolidated Balance Sheets (USD $)
Sep. 30, 2017
Dec. 31, 2016
Current assets:
 
 
Cash and cash equivalents
$ 8,404,332 
$ 1,834,018 
Other current assets
836,756 
540,053 
Total current assets
9,241,088 
2,374,071 
Property and equipment, net
5,062 
6,217 
Other assets:
 
 
Goodwill
7,647,266 
272,315 
In-process research and development
118,600 
118,600 
Deferred financing costs
1,901 
Total assets
17,012,016 
2,773,104 
Current liabilities:
 
 
Accounts payable
539,440 
383,411 
Accrued expenses
1,711,300 
438,028 
Total liabilities
2,250,740 
821,439 
Series B Convertible Redeemable Preferred stock, $0.0001 par value; none and 970,238 shares authorized, issued and outstanding at September 30, 2017 and December 31, 2016, respectively
8,022,219 
Series A Convertible Redeemable Preferred stock, $0.0001 par value; none and 638,416 shares authorized, issued and outstanding at September 30, 2017 and December 31, 2016, respectively
4,114,221 
Convertible Redeemable Preferred stock
12,136,440 
Stockholders' equity:
 
 
Preferred stock, no par value; authorized 10,000,000 shares; none issued and outstanding
Common stock, $0.01 par value; authorized 150,000,000 shares; 6,450,766 and 2,450,000 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively
645 
246 
Additional paid in capital
36,098,222 
1,172,200 
Accumulated deficit
(21,337,591)
(11,357,221)
Total stockholders' equity (deficit)
14,761,276 
(10,184,775)
Total liabilities, redeemable preferred stock and stockholders' equity (deficit)
$ 17,012,016 
$ 2,773,104 
Consolidated Balance Sheets (Parenthetical) (USD $)
Sep. 30, 2017
Dec. 31, 2016
Preferred stock, no par value
$ 0 
$ 0 
Preferred stock, shares authorized
10,000,000 
10,000,000 
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value
$ 0.01 
$ 0.01 
Common stock, shares authorized
150,000,000 
150,000,000 
Common stock, shares issued
6,450,766 
2,450,000 
Common stock, shares outstanding
6,450,766 
2,450,000 
Preferred Class A Redeemable[Member]
 
 
Preferred stock, par value
$ 0.0001 
$ 0.0001 
Preferred stock, shares authorized
638,416 
Preferred stock, shares issued
638,416 
Preferred stock, shares outstanding
638,416 
Preferred Class B Redeemable[Member]
 
 
Preferred stock, par value
$ 0.0001 
$ 0.0001 
Preferred stock, shares authorized
970,238 
Preferred stock, shares issued
970,238 
Preferred stock, shares outstanding
970,238 
Consolidated Statements of Operations (USD $)
3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Operating expenses:
 
 
 
 
Research and development
$ 2,057,421 
$ 1,610,822 
$ 6,948,816 
$ 3,510,118 
General and administrative
1,302,401 
274,512 
2,792,424 
1,054,479 
Loss from operations
3,359,822 
1,885,334 
9,741,240 
4,564,597 
Other income (expense):
 
 
 
 
Interest income
2,993 
136 
4,819 
174 
Interest expense
(120,229)
(242,982)
Loss on disposal of asset
(967)
(967)
Total other income (expense), net
(118,203)
136 
(239,130)
174 
Net loss
$ (3,478,025)
$ (1,885,198)
$ (9,980,370)
$ (4,564,423)
Basic and diluted loss per share
$ (1.09)
$ (0.77)
$ (3.69)
$ (1.86)
Weighted average common shares outstanding - basic and diluted
3,199,796 
2,450,000 
2,702,678 
2,450,000 
Consolidated Statements of Cash Flows (USD $)
9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Cash flows from operating activities
 
 
Net loss
$ (9,980,370)
$ (4,564,423)
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
Non-cash interest expense
242,982 
Share-based compensation
136,617 
39,031 
Depreciation
2,711 
2,627 
Loss on disposal of asset
967 
Write-off of deferred financing costs
1,901 
69,896 
Changes in:
 
 
Prepaid expenses
(291,703)
(36,902)
Accounts payable
156,029 
(60,803)
Accrued expenses
(157,890)
(23,591)
Net cash used in operating activities
(9,888,756)
(4,574,165)
Cash flows from investing activities
 
 
Cash acquired in merger, net of payment in lieu of fractional shares
1,030,123 
Purchase of property and equipment
(2,523)
(1,582)
Net cash provided by (used in) investing activities
1,027,600 
(1,582)
Cash flows from financing activities
 
 
Proceeds from issuance of common stock
10,000,000 
Proceeds from issues of Preferred Series B, net
7,994,834 
Deferred financing costs
(68,530)
Proceeds from convertible notes payable
5,500,000 
Net cash provided/(used) in financing activities
15,431,470 
7,994,834 
Net increase in cash and cash equivalents
6,570,314 
3,419,087 
Cash and cash equivalents at beginning of period
1,834,018 
798,545 
Cash and cash equivalents at end of period
8,404,332 
4,217,632 
Supplemental non-cash financing transactions:
 
 
Accretion of issuance costs on Series A Convertible Redeemable Preferred stock
51,943 
11,130 
Accretion of issuance costs on Series B Convertible Redeemable Preferred stock
127,780 
Conversion of Series A Convertible Redeemable Preferred stock to common stock
4,166,164 
Conversion of Series B Convertible Redeemable Preferred stock to common stock
8,149,995 
Conversion of convertible notes payable and accrued interest to common stock
5,674,452 
Issuance of common stock in Merger (Note 1)
$ 6,978,916 
$ 0 
1. Nature of Operations and Basis of Presentation
Nature of Operations and Basis of Presentation

Business

 

Acer Therapeutics Inc. (“Acer”) is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for patients with serious rare and ultra-rare diseases with critical unmet medical need. Acer’s late-stage clinical pipeline includes two candidates for severe genetic disorders for which there are few or no FDA-approved treatments: EDSIVO™ (celiprolol) for vascular Ehlers-Danlos Syndrome (“vEDS”), and ACER-001 (a fully taste-masked, immediate release formulation of sodium phenylbutyrate) for urea cycle disorders (“UCD”) and Maple Syrup Urine Disease (“MSUD”). There are no FDA-approved drugs for vEDS and MSUD and limited options for UCD, which collectively impact more than 4,000 patients in the United States. Acer’s products have clinical proof-of-concept and mechanistic differentiation, and Acer intends to seek approval for them in the U.S. by using the regulatory pathway established under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, or FFDCA, that allows an applicant to rely for approval at least in part on third-party data, which is expected to expedite the preparation, submission, and approval of a marketing application.

 

Since its inception, Acer has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets and raising capital.

 

The accompanying condensed consolidated financial statements for periods prior to August 2016 include the accounts of Acer and its wholly-owned subsidiaries, Acer Therapeutics Inc., a Delaware corporation, and Anchor Therapeutics, Inc. (“Anchor”) (collectively referred to as the “Company”). All intercompany balances and transactions are eliminated. See Merger and Reverse Stock Split section below.

 

The Company is subject to a number of risks similar to other companies in its industry including rapid technological change, uncertainty of market acceptance of products, competition from larger companies with substitute products, availability of future financing and dependence on key personnel.

 

Merger and Reverse Stock Split

 

On September 19, 2017, Acer Therapeutics Inc., a Texas corporation, formerly known as Opexa Therapeutics, Inc. (the “Registrant”), completed its business combination with what was then known as “Acer Therapeutics Inc.,” a Delaware corporation (“Private Acer”), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of June 30, 2017, by and among the Registrant, Opexa Merger Sub, Inc. (“Merger Sub”) and Private Acer (the “Merger Agreement”), pursuant to which Merger Sub merged with and into Private Acer, with Private Acer surviving as a wholly-owned subsidiary of the Registrant (the “Merger”). This transaction was approved by the Registrant’s shareholders at a special meeting of its shareholders on September 19, 2017 (the “Special Meeting”). Also on September 19, 2017, in connection with, and prior to the completion of, the Merger, the Registrant effected a 1-for-10.355527 reverse stock split of its then outstanding common stock (the “Reverse Split”) and immediately following the Merger, the Registrant changed its name to “Acer Therapeutics Inc.” pursuant to amendments to its certificate of formation filed with the Texas Secretary of State on September 19, 2017. All share numbers in this report have been adjusted to reflect the Reverse Split.

 

Following the completion of the Merger, the business conducted by the Registrant became primarily the business conducted by Private Acer, which is a pharmaceutical company that acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need.

 

Under the terms of the Merger Agreement, the Registrant issued shares of its common stock to Private Acer’s stockholders, at an exchange rate of one share of common stock (after giving effect to the Reverse Split and the conversion of Private Acer’s Series A and Series B preferred stock and convertible debt) in exchange for each share of Private Acer common stock outstanding immediately prior to the Merger. The exchange rate was determined through arm’s length negotiations between the Registrant and Private Acer. The Registrant also assumed all issued and outstanding stock options under the Acer Therapeutics Inc. 2013 Stock Incentive Plan, with such stock options henceforth representing the right to purchase a number of shares of the Registrant’s common stock equal to the number of shares of Private Acer’s common stock previously represented by such stock options.

 

Immediately after the Merger, (i) there were approximately 6.5 million shares of the Registrant’s common stock outstanding; (ii) the former Private Acer stockholders, including investors in the Concurrent Financing (as defined below), owned approximately 89% of the outstanding common stock of the Registrant; and (iii) the Registrant’s shareholders immediately prior to the Merger, whose shares of the Registrant’s common stock remain outstanding after the Merger, owned approximately 11% of the outstanding common stock of the Registrant.

 

The issuance of the shares of the Registrant’s common stock to the former stockholders of Private Acer was registered with the U.S. Securities and Exchange Commission (the “SEC”) on a Registration Statement on Form S-4 (Reg. No. 333-219358) (the “Registration Statement”). Immediately prior to the Merger, Private Acer issued and sold an aggregate of approximately $15.7 million (inclusive of the conversion of approximately $5.7 million of principal and accrued interest on outstanding convertible promissory notes issued by Private Acer) of shares of Private Acer’s common stock (the “Concurrent Financing”) to certain current stockholders of Private Acer and certain new investors at a per share price of $9.47.

 

Accounting principles generally accepted in the United States require that a company whose security holders retain the majority voting interest in the combined business be treated as the acquirer for financial reporting purposes. Accordingly, the Merger was accounted for as a reverse acquisition whereby Private Acer was treated as the acquirer for accounting and financial reporting purposes. As such, references to the results of operations for the nine months ended September 30, 2017 include the historical results of Private Acer from January 1, 2017 through September 18, 2017 and include the consolidated results of the combined company from September 19, 2017 through September 30, 2017.

 

The Registrant’s common stock continued to trade on a pre-split basis through the close of business on Wednesday, September 20, 2017 on The NASDAQ Capital Market under the ticker symbol “OPXA.” Commencing with the open of trading on Thursday, September 21, 2017, the post-split shares began trading on The NASDAQ Capital Market under the ticker symbol “ACER.” On September 21, 2017, the Registrant’s Series M Warrants, previously trading through the close of business on Wednesday, September 20, 2017 under the ticker symbol “OPXAW,” commenced trading on The NASDAQ Capital Market, under the ticker symbol “ACERW.” The Registrant’s common stock and Series M Warrants have new CUSIP numbers of 00444P 108 and 00444P 116, respectively.

 

Private Acer was incorporated on December 26, 2013 as part of a reorganization whereby Acer Therapeutics, LLC was converted into a corporation organized under the laws of the state of Delaware. On March 20, 2015, Private Acer acquired Anchor, with Anchor becoming a wholly-owned subsidiary of Private Acer. On August 19, 2016, Anchor’s pepducin business reverted back to the pre-acquisition holders of Anchor’s equity.

 

The accompanying condensed consolidated financial statements include the activities of Private Acer as of and for the respective periods presented.

 

Basis of Presentation

 

The accompanying condensed consolidated balance sheet as of September 30, 2017 and the condensed consolidated statements of operations and cash flows for the three and nine months ended September 30, 2017 and 2016 are unaudited and have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Regulation S-X. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company’s financial position as of September 30, 2017, the results of operations for the three and nine months ended September 30, 2017 and 2016, and the cash flows for the nine months ended September 30, 2017 and 2016. The results of operations for the three and nine months ended September 30, 2017 are not necessarily indicative of the results to be expected for the year ending December 31, 2017 or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2016 included herein was derived from the audited consolidated financial statements as of that date. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in the Registration Statement.

 

Going Concern Uncertainty

 

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has experienced recurring losses since inception. The Company has relied on raising capital to finance its operations.

 

The Company plans to raise capital through equity and/or debt financings. There is no assurance, however, that the Company will be able to raise sufficient capital to fund its operations on terms that are acceptable, or that its operations will ever be profitable.

 

There is substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the accompanying financial statements are available to be issued and these financial statements do not include any adjustments relating to the recoverability of recorded asset amounts that might be necessary as a result of the above uncertainty. Based on available resources, the Company believes that its cash and cash equivalents currently on hand are sufficient to fund its anticipated operating and capital requirements through the first half of 2018.

 

2. Significant Accounting Polices
Significant Accounting Polices

A summary of the significant accounting policies followed by the Company in the preparation of the accompanying condensed consolidated financial statements follows:

 

Business Combinations

Assets acquired and liabilities assumed as part of a business acquisition are generally recorded at their fair value at the date of acquisition. The excess of purchase price over the fair value of assets acquired and liabilities assumed is recorded as goodwill. Determining fair value of identifiable assets, particularly intangibles, and liabilities acquired also requires management to make estimates, which are based on all available information and in some cases assumptions with respect to the timing and amount of future revenues and expenses associated with an asset. Accounting for business acquisitions may require management to make judgments and estimates as to fair value of consideration transferred. This judgment and determination may affect the amount of consideration paid that is allocable to assets and liabilities acquired in the business purchase transaction.

Share-Based Compensation

 

The Company records share-based payments at fair value. The measurement date for compensation expense related to employee awards is generally the date of the grant. The measurement date for compensation expense related to nonemployee awards is generally the date that the performance of the awards is completed and, until such time, the fair value of the awards is remeasured at the end of each reporting period. Accordingly, the ultimate expense is not fixed until such awards are vested. The fair value of awards, net of expected forfeitures, is recognized as expense in the statement of operations over the requisite service period, which is generally the vesting period. The fair value of options is calculated using the Black-Scholes option pricing model. This option valuation model requires input of assumptions including, among others, the volatility of stock price, the expected term of the option, and the risk-free interest rate.

 

Use of Estimates

 

The Company’s accounting principles require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting period. Estimates having relatively higher significance include the accounting for acquisitions, stock-based compensation, and income taxes. Actual results could differ from those estimates and changes in estimates may occur.

 

Basic and Diluted Net Loss per Common Share

 

Basic and diluted net loss per common share is computed by dividing net loss in each period by the weighted average number of shares of common stock outstanding during such period. For the periods presented, common stock equivalents, consisting of options, convertible redeemable preferred stock, warrants and convertible notes payable, were not included in the calculation of the diluted loss per share because they were anti-dilutive.

 

Recently Adopted Accounting Pronouncements

In March 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting, or ASU No. 2016-09, which simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification of cash flows. The Company adopted ASU No. 2016-09 as of January 1, 2017. Under the new standard, all excess tax benefits and tax deficiencies are recognized as income tax expense or benefit in the statement of operations. The tax effects of exercised or vested awards are treated as discrete items in the reporting period in which they occur. The Company applied the modified retrospective adoption approach upon adoption of the standard, and prior periods have not been adjusted. The Company elected to recognize forfeitures related to employee share-based payments as they occur. There was no material impact on the Company’s financial statements as a result of the adoption of this guidance.

Recently Issued Accounting Pronouncements

Revenue from Contracts with Customers

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), or ASU 2014-09. Subsequently, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606), which adjusted the effective date of ASU 2014-09; ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), which amends the principal-versus-agent implementation guidance and illustrations in ASU 2014-09; ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies identifying performance obligations and licensing implementation guidance and illustrations in ASU 2014-09; ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which addresses implementation issues and is intended to reduce the cost and complexity of applying the new revenue standard in ASU 2014-09; and ASU No. 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842): Amendments to SEC Paragraphs Pursuant to the Staff Announcement at the July 20, 2017 EITF Meeting and Rescission of Prior SEC Staff Announcements and Observer Comments (SEC Update), which codifies recent announcements by the SEC staff, or collectively, the Revenue ASUs.

The Revenue ASUs provide an accounting standard for a single comprehensive model for use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. The accounting standard is effective for interim and annual periods beginning after December 15, 2017, with an option to early adopt for interim and annual periods beginning after December 15, 2016. The guidance permits two methods of adoption: retrospectively to each prior reporting period presented (the full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). The Company will adopt the new standard effective January 1, 2018 under the modified retrospective method. The Company has allocated internal resources to the implementation and is in the process of determining the impact of the Revenue ASUs on its financial statements; however, the adoption of the Revenue ASUs may have a material impact on revenue recognition, its notes to consolidated financial statements and its internal controls over financial reporting. Currently, The Company does not have sources of revenue but future arrangements may be impacted by the adoption of the Revenue ASUs noted above.

Other Recent Accounting Pronouncements

   In January 2017, the FASB issued ASU No. 2017-04, Intangibles – Goodwill and Other (Topic 350). This ASU eliminates step 2 from the goodwill impairment test by comparing the fair value of a reporting unit with the carrying amount of the reporting unit. If the carrying amount exceeds the fair value, an impairment charge for the excess is recorded. The amendments of this ASU are effective for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently evaluating the impact of the adoption of this ASU on the consolidated financial statements.

  

In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. The new guidance will reduce diversity in practice and result in fewer changes to the terms of an award being accounted for as modifications. Under ASU 2017-09, an entity will not apply modification accounting to a share-based payment award if the award’s fair value, vesting conditions and classification as an equity or liability instrument are the same immediately before and after the change. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. The guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. The Company is evaluating the impact of the adoption of this guidance on its financial statements, but does not expect it to have a material impact.

 

In July 2017, FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception (Update). Part I of this Update addresses the complexity of accounting for certain financial instruments with down round features by simplifying the accounting for these instruments. This Update requires companies to disregard the down round feature when assessing whether an instrument, such as a warrant, is indexed to its own stock, for purposes of determining liability or equity classification. This will change the classification of certain warrants with down round features from a liability to equity. Also, entities must adjust their basic earnings per share (EPS) calculation for the effect of the down round provision when triggered (that is, when the exercise price of the related equity-linked financial instrument is adjusted downward because of the down round feature). That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. An entity will also recognize the effect of the trigger within equity. The guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. The Company is evaluating the impact of the adoption of this guidance on its financial statements. Part II of this Update addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification. The amendments in Part II of this Update re-characterize the indefinite deferral of certain provisions of Topic 480, Distinguishing Liabilities from Equity, that previously were presented as pending content in the Codification, to a scope exception, and do not have any accounting effect.

 

3. Purchase Accounting
Purchase Accounting

The Merger was accounted for using the purchase method of accounting as a reverse acquisition.  In a reverse acquisition, the post-acquisition net assets of the surviving combined company includes the historical cost basis of the net assets of the accounting acquirer (Private Acer) plus the fair value of the net assets of the accounting acquiree (the Registrant). Further, under the purchase method, the purchase price is allocated to the assets acquired, liabilities assumed, and identifiable intangible assets based on their estimated fair values, with the remaining excess purchase price over net assets acquired allocated to goodwill.

 

 The fair value of the consideration transferred in the Merger was $6,978,916 and was calculated as the number of shares of common stock that Private Acer issued (adjusted for the exchange ratio) in order for the Registrant’s shareholders to hold an 11% equity interest in the combined company post-acquisition, multiplied by the estimated fair value of Private Acer’s common stock on the acquisition date.  The estimated fair value of Private Acer’s common stock was based on the offering price of the common stock sold in the private placement which was both completed concurrently with and conditioned upon the closing of the Merger.  This price was determined to be the best indication of fair value on that date since the price was based on an arm’s length negotiation with a group consisting of both new and existing investors of Private Acer that had been advised of the pending Merger and assumed similar liquidity risk as those investors holding the majority of shares being valued as purchase consideration.

 

 The following table summarizes the Company’s determination of fair values of the assets acquired and the liabilities assumed as of the date of acquisition.

 

Consideration - issuance of securities and cash paid for fractional shares   $ 7,007,069  
Assets acquired and liabilities assumed:        
Cash   $ 1,058,276  
Other assets     5,000  
Accrued liabilities     (1,431,158 )
Goodwill     7,374,951  
Total purchase price   $ 7,007,069  

 

The Company determined that the acquired legacy technology of the Registrant had no value as of the date of the acquisition.

 

Goodwill represents the excess of the purchase price (consideration paid plus net liabilities assumed) of an acquired business over the fair value of the underlying net tangible and intangible assets. Goodwill includes the value of the Registrant’s standing as a public entity. None of the goodwill associated with the Merger is deductible for income tax purposes. 

 

There were no changes in goodwill during the period ended September 30, 2017, after the initial purchase accounting. 

 

The Company is required to perform an annual impairment test related to goodwill which is performed in the fourth quarter of each year, or sooner if changes in circumstances suggest that the carrying value of an asset may not be recoverable.

 

Unaudited pro forma operating results, assuming the Merger occurred as of January 1, 2016, are as follows:

 

    Three Months Ended     Nine Months Ended  
    September 30,     September 30,  
    2017     2016     2017     2016  
                         
Net loss   $ (3,478,025 )   $ (1,885,198 )   $ (9,980,370 )   $ (4,564,423 )
Net loss per share - basic and diluted   $ (1.09 )   $ (0.77 )   $ (3.69 )   $ (1.86 )

 

4. Property and Equipment
Property and Equipment

Property and equipment consisted of the following at September 30, 2017 and December 31, 2016:

 

   

September 30,

2017

   

December 31,

2016

 
             
Computer hardware and software   $ 10,706     $ 10,862  
Less accumulated depreciation     (5,645 )     (4,645 )
                 
    $ 5,062     $ 6,217  

 

5. Accrued Expenses
Accrued Expenses

Accrued expenses consisted of the following at September 30, 2017 and December 31, 2016:

 

   

September 30,

2017

   

December 31,

2016

 
             
Accrued legal   $ 248,710     $ 21,477  
Accrued pre-commercial costs     317,567        
Accrued consulting     94,169       13,105  
Accrued audit and tax     92,437       39,820  
Accrued license fees     893,949       205,444  
Accrued contract manufacturing           126,700  
Accrued contract research     35,657       16,800  
Accrued miscellaneous expenses     28,811       14,682  
    $ 1,711,300     $ 438,028  

 

6. Convertible Notes Payable
Convertible Notes Payable

On March 22, 2017, Private Acer issued senior secured convertible notes payable (the “2017 Notes”) to existing investors and a vendor in the aggregate principal amount of $3,125,000. The 2017 Notes accrued interest at 10% per annum and matured on the earlier of (i) March 22, 2018 (the “Maturity Date”) or (ii) upon a Change in Control of Private Acer, as defined therein.

 

On May 31, 2017, Private Acer issued additional 2017 Notes to existing investors and a vendor in the aggregate principal amount of $2,375,000.

 

The 2017 Notes were convertible into common stock upon a Qualified Financing (as defined therein), a Change in Control, or an optional conversion by the holder. Conversion upon a Qualified Financing was at a price per share equal to the price per share paid for the shares sold in the Qualified Financing less a discount of: (i) 0%, if a Qualified Financing occurred on or before June 30, 2017; (ii) 10%, if a Qualified Financing occurred after June 30, 2017 but on or before September 1, 2017; or (iii) 20%, if a Qualified Financing occurred after September 1, 2017. Conversion upon a Change in Control was at the discretion of the holder such that Private Acer would pay each holder the outstanding balance on their respective note or the note would be converted at a price per share equal to the lesser of $16.57 and the price per share of common stock paid to the holders of the common stock in such Change in Control. Conversion under an optional conversion by the holder was at a price per share of $16.57 based on the outstanding balance of the note.

 

Upon the issuance of the 2017 Notes, Private Acer evaluated all terms of the 2017 Notes, including the Change in Control provision, to identify any embedded features that required bifurcation and recording as derivative instruments. Private Acer determined that there were no such features requiring separate accounting.

 

In connection with the 2017 Notes, Private Acer incurred debt issuance costs of $68,530 and recorded them as a debt discount. During the nine months ended September 30, 2017, the Company recognized $242,982 of interest expense, which includes $68,530 in amortization of debt discount and $174,452 of accrued interest on the 2017 Notes. The principal of $5,500,000 and accrued interest of $174,452 on the 2017 Notes converted into 599,201 fully-paid shares of common stock at the time of the Merger described in Note 1, with no discount on the conversion.

 

7. Commitments
Commitments

License Agreements

 

In August 2016, Private Acer signed an agreement with the Greater Paris University Hospitals AP-HP (via its Department of Clinical Research and Development) granting Private Acer exclusive worldwide rights to access and use data from a randomized controlled clinical study of celiprolol. The Company will use this pivotal clinical data to support a New Drug Application (“NDA”) regulatory filing for its lead product, celiprolol, for the treatment of vEDS. The agreement requires Private Acer to make certain upfront payments to AP-HP, as well as reimburse certain costs, and make payments upon achievement of defined milestones and payment of royalties on net sales of celiprolol over the royalty term.

 

In April 2014, Private Acer obtained exclusive rights to intellectual property relating to ACER-001 and preclinical and clinical data, through an exclusive license agreement with Baylor College of Medicine (“BCM”). Under the terms of the agreement, as amended, Private Acer has worldwide exclusive rights to develop, manufacture, use, sell and import Licensed Products as defined in the agreement. The license agreement requires Private Acer to make certain upfront and annual payments to BCM, as well as reimburse certain legal costs, and make payments upon achievement of defined milestones and payment of royalties on net sales of any developed product over the royalty term.

 

Litigation

 

From time to time, the Company or its subsidiaries may become involved in litigation or proceedings relating to claims arising from the ordinary course of business.

 

On September 27, 2017, Piper Jaffray & Co. filed a lawsuit against Private Acer, Piper Jaffray & Co. v. Acer Therapeutics Inc., Index No. 656055/2017, in the Supreme Court of the State of New York, County of New York.  The complaint alleges that Private Acer breached its obligations to Piper Jaffray & Co. pursuant to an August 30, 2016 engagement letter between the parties and an April 28, 2017 addendum thereto by failing to pay Piper Jaffray & Co. (i) a fee of $1,097,207 in connection with the financing which closed on September 19, 2017 for aggregate consideration of approximately $15.7 million (including the conversion of the 2017 Notes described in Note 6) and (ii) $67,496 in reimbursement for expenses incurred by Piper Jaffray & Co. pursuant to the engagement letter.  On November 10, 2017, Private Acer filed an answer and counterclaim in the lawsuit, denying Piper Jaffray & Co.’s breach of contract allegation, asserting several defenses, and bringing several counterclaims, including claims for breach of contract and breach of the duty of good faith and fair dealing.  The Company has not recorded a liability as of September 30, 2017 because a potential loss is not probable or reasonably estimable given the preliminary nature of the proceedings.

 

8. Stockholders' Equity
Stockholders' Equity

Immediately prior to the consummation of the Merger described in Note 1, (i) Private Acer’s Series A Convertible Redeemable Preferred stock and Series B Convertible Redeemable Preferred stock were converted into 638,416 and 970,238 shares of common stock, respectively, (ii) Private Acer’s 2017 Notes and accrued interest totaling $5,674,452 were converted into 599,201 shares of common stock, and (iii) 1,055,961 shares of common stock were sold for $9.47 per share generating $10,000,000 of gross proceeds.

 

At the closing of the Merger, 736,950 shares of common stock were held by existing shareholders of the Registrant.

 

2013 Stock Incentive Plan

 

Private Acer’s 2013 Stock Incentive Plan, as amended (the “2013 Plan”), which was assumed by Acer in connection with the Merger, provides for the granting of up to 165,000 shares of common stock as incentive or non-qualified stock options and/or restricted common stock to employees, officers, directors, consultants and advisers. Option awards are generally granted with an exercise price equal to the fair value of the common stock at the date of grant and have contractual terms of 10 years. A summary of option activity under the 2013 Plan for the nine months ended September 30, 2017 is as follows:

 

   

Number of

Shares

   

Weighted

Average

Exercise

Price

   

Weighted

Average

Remaining

Contractual

Term (Years)

 
Options outstanding at December 31, 2016     122,000     $ 2.55        
Granted     48,625       7.21        
Exercised                  
Cancelled/forfeited     (5,625 )     2.55        
Options outstanding at September 30, 2017     165,000     $ 3.92       7.54  
Options exercisable at September 30, 2017     123,562     $ 3.47       8.46  

 

At September 30, 2017, there was approximately $99,600 of unrecognized compensation expense related to the share-based compensation arrangements granted under the 2013 Plan and the average remaining vesting period is 0.58 years. The weighted average grant date fair value of options granted during the nine months ended September 30, 2017 was $3.76.

 

2010 Stock Incentive Plan

 

Acer’s Amended and Restated 2010 Stock Incentive Plan, as amended (the “2010 Plan”), provides for the granting of up to 470,000 shares of common stock as incentive or non-qualified stock options, stock appreciation rights, restricted stock units and/or restricted common stock to employees, officers, directors, consultants and advisers. Option awards are generally granted with an exercise price equal to the fair value of the common stock at the date of grant and have contractual terms of 10 years. All outstanding and unexercised equity awards (representing 22,061 underlying shares) under the 2010 Plan were cancelled in connection with the Merger.

 

Warrants

 

A summary of warrant activity for the three months ended September 30, 2017 is presented below:

 

    Number of Shares     Weighted Average Exercise Price    

Weighted Average Remaining Contract Term

(# years)

    Intrinsic Value  
Assumed in the Merger at September 19, 2017     317,630   $ 123.61      .54        
Outstanding and exercisable at September 30, 2017     317,630   $ 123.61       .54        

 

9. Net Loss Per Share
Net Loss Per Share

Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted net loss per share is the same as basic net loss per common share, since the effects of potentially dilutive securities are antidilutive.

 

As of September 30, 2017 and 2016, the number of shares of common stock underlying potentially dilutive securities include:

 

    September 30,  
    2017     2016  
             
Convertible redeemable preferred stock           638,416  
Warrants     317,630        
Options to purchase common stock     165,000       122,000  
                 
Total     482,630       760,416  

 

 

10. Subsequent Events
Subsequent Events

On October 4, 2017, the Company’s Board of Directors granted non-qualified stock options under the 2010 Plan to purchase an aggregate of (i) 218,600 shares of the Company’s common stock to executive officers and employees and (ii) 30,000 shares of the Company’s common stock to outside non-employee directors, all at an exercise price of $15.34 per share. Stock options granted to executive officers and employees vest over a four-year period, with 25% vesting on the one-year anniversary of the grant date and the remaining 75% vesting quarterly over the remaining three years, assuming continued service, and with vesting acceleration in full immediately prior to a change in control. Stock options granted to outside non-employee directors vest either (a) in full on the one-year anniversary of the grant date, assuming continued service, for awards to continuing directors, with vesting acceleration in full immediately prior to a change in control, or (b) quarterly over a three-year period, assuming continued service, for awards to new directors, with vesting acceleration in full immediately prior to a change in control. On November 8, 2017, the Company’s Board of Directors granted a non-qualified stock option to purchase 25,000 shares of the Company’s common stock to an employee with an exercise price of $17.51, which vests over a four-year period, with 25% vesting on the one-year anniversary of the grant date and the remaining 75% vesting quarterly over the remaining three years, assuming continued service, and with vesting acceleration in full immediately prior to a change in control.

 

2. Significant Accounting Polices (Policies)

The Company records share-based payments at fair value. The measurement date for compensation expense related to employee awards is generally the date of the grant. The measurement date for compensation expense related to nonemployee awards is generally the date that the performance of the awards is completed and, until such time, the fair value of the awards is remeasured at the end of each reporting period. Accordingly, the ultimate expense is not fixed until such awards are vested. The fair value of awards, net of expected forfeitures, is recognized as expense in the statement of operations over the requisite service period, which is generally the vesting period. The fair value of options is calculated using the Black-Scholes option pricing model. This option valuation model requires input of assumptions including, among others, the volatility of stock price, the expected term of the option, and the risk-free interest rate.

 

Assets acquired and liabilities assumed as part of a business acquisition are generally recorded at their fair value at the date of acquisition. The excess of purchase price over the fair value of assets acquired and liabilities assumed is recorded as goodwill. Determining fair value of identifiable assets, particularly intangibles, and liabilities acquired also requires management to make estimates, which are based on all available information and in some cases assumptions with respect to the timing and amount of future revenues and expenses associated with an asset. Accounting for business acquisitions may require management to make judgments and estimates as to fair value of consideration transferred. This judgment and determination may affect the amount of consideration paid that is allocable to assets and liabilities acquired in the business purchase transaction.

The Company’s accounting principles require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting period. Estimates having relatively higher significance include the accounting for acquisitions, stock-based compensation, and income taxes. Actual results could differ from those estimates and changes in estimates may occur.

 

 

Basic and diluted net loss per common share is computed by dividing net loss in each period by the weighted average number of shares of common stock outstanding during such period. For the periods presented, common stock equivalents, consisting of options, convertible redeemable preferred stock, warrants and convertible notes payable, were not included in the calculation of the diluted loss per share because they were anti-dilutive.

Recently Adopted Accounting Pronouncements

In March 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting, or ASU No. 2016-09, which simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification of cash flows. The Company adopted ASU No. 2016-09 as of January 1, 2017. Under the new standard, all excess tax benefits and tax deficiencies are recognized as income tax expense or benefit in the statement of operations. The tax effects of exercised or vested awards are treated as discrete items in the reporting period in which they occur. The Company applied the modified retrospective adoption approach upon adoption of the standard, and prior periods have not been adjusted. The Company elected to recognize forfeitures related to employee share-based payments as they occur. There was no material impact on the Company’s financial statements as a result of the adoption of this guidance.

Recently Issued Accounting Pronouncements

Revenue from Contracts with Customers

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), or ASU 2014-09. Subsequently, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606), which adjusted the effective date of ASU 2014-09; ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), which amends the principal-versus-agent implementation guidance and illustrations in ASU 2014-09; ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies identifying performance obligations and licensing implementation guidance and illustrations in ASU 2014-09; ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which addresses implementation issues and is intended to reduce the cost and complexity of applying the new revenue standard in ASU 2014-09; and ASU No. 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842): Amendments to SEC Paragraphs Pursuant to the Staff Announcement at the July 20, 2017 EITF Meeting and Rescission of Prior SEC Staff Announcements and Observer Comments (SEC Update), which codifies recent announcements by the SEC staff, or collectively, the Revenue ASUs.

The Revenue ASUs provide an accounting standard for a single comprehensive model for use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. The accounting standard is effective for interim and annual periods beginning after December 15, 2017, with an option to early adopt for interim and annual periods beginning after December 15, 2016. The guidance permits two methods of adoption: retrospectively to each prior reporting period presented (the full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). The Company will adopt the new standard effective January 1, 2018 under the modified retrospective method. The Company has allocated internal resources to the implementation and is in the process of determining the impact of the Revenue ASUs on its financial statements; however, the adoption of the Revenue ASUs may have a material impact on revenue recognition, its notes to consolidated financial statements and its internal controls over financial reporting. Currently, The Company does not have sources of revenue but future arrangements may be impacted by the adoption of the Revenue ASUs noted above.

Other Recent Accounting Pronouncements

   In January 2017, the FASB issued ASU No. 2017-04, Intangibles – Goodwill and Other (Topic 350). This ASU eliminates step 2 from the goodwill impairment test by comparing the fair value of a reporting unit with the carrying amount of the reporting unit. If the carrying amount exceeds the fair value, an impairment charge for the excess is recorded. The amendments of this ASU are effective for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently evaluating the impact of the adoption of this ASU on the consolidated financial statements.

  

In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. The new guidance will reduce diversity in practice and result in fewer changes to the terms of an award being accounted for as modifications. Under ASU 2017-09, an entity will not apply modification accounting to a share-based payment award if the award’s fair value, vesting conditions and classification as an equity or liability instrument are the same immediately before and after the change. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. The guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. The Company is evaluating the impact of the adoption of this guidance on its financial statements, but does not expect it to have a material impact.

 

In July 2017, FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception (Update). Part I of this Update addresses the complexity of accounting for certain financial instruments with down round features by simplifying the accounting for these instruments. This Update requires companies to disregard the down round feature when assessing whether an instrument, such as a warrant, is indexed to its own stock, for purposes of determining liability or equity classification. This will change the classification of certain warrants with down round features from a liability to equity. Also, entities must adjust their basic earnings per share (EPS) calculation for the effect of the down round provision when triggered (that is, when the exercise price of the related equity-linked financial instrument is adjusted downward because of the down round feature). That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. An entity will also recognize the effect of the trigger within equity. The guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. The Company is evaluating the impact of the adoption of this guidance on its financial statements. Part II of this Update addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification. The amendments in Part II of this Update re-characterize the indefinite deferral of certain provisions of Topic 480, Distinguishing Liabilities from Equity, that previously were presented as pending content in the Codification, to a scope exception, and do not have any accounting effect.

3. Purchase Accounting (Tables)
Consideration - issuance of securities and cash paid for fractional shares   $ 7,007,069  
Assets acquired and liabilities assumed:        
Cash   $ 1,058,276  
Other assets     5,000  
Accrued liabilities     (1,431,158 )
Goodwill     7,374,951  
Total purchase price   $ 7,007,069  
    Three Months Ended     Nine Months Ended  
    September 30,     September 30,  
    2017     2016     2017     2016  
                         
Net loss   $ (3,478,025 )   $ (1,885,198 )   $ (9,980,370 )   $ (4,564,423 )
Net loss per share - basic and diluted   $ (1.09 )   $ (0.77 )   $ (3.69 )   $ (1.86 )
4. Property and Equipment (Tables)
Property and equipment
   

September 30,

2017

   

December 31,

2016

 
             
Computer hardware and software   $ 10,706     $ 10,862  
Less accumulated depreciation     (5,645 )     (4,645 )
                 
    $ 5,062     $ 6,217  
5. Accrued Expenses (Tables)
Accrued expenses
   

September 30,

2017

   

December 31,

2016

 
             
Accrued legal   $ 248,710     $ 21,477  
Accrued pre-commercial costs     317,567        
Accrued consulting     94,169       13,105  
Accrued audit and tax     92,437       39,820  
Accrued license fees     893,949       205,444  
Accrued contract manufacturing           126,700  
Accrued contract research     35,657       16,800  
Accrued miscellaneous expenses     28,811       14,682  
    $ 1,711,300     $ 438,028  
8. Stockholders' Equity (Tables)
Stock option and warrant activity
   

Number of

Shares

   

Weighted

Average

Exercise

Price

   

Weighted

Average

Remaining

Contractual

Term (Years)

 
Options outstanding at December 31, 2016     122,000     $ 2.55        
Granted     48,625       7.21        
Exercised                  
Cancelled/forfeited     (5,625 )     2.55        
Options outstanding at September 30, 2017     165,000     $ 3.92       7.54  
Options exercisable at September 30, 2017     123,562     $ 3.47       8.46  

 

    Number of Shares     Weighted Average Exercise Price    

Weighted Average Remaining Contract Term

(# years)

    Intrinsic Value  
Assumed in the Merger at September 19, 2017     317,630   $ 123.61      .54        
Outstanding and exercisable at September 30, 2017     317,630   $ 123.61       .54        

 

9. Net Loss Per Share (Tables)
Shares potentially dilutive
    September 30,  
    2017     2016  
             
Convertible redeemable preferred stock           638,416  
Warrants     317,630        
Options to purchase common stock     165,000       122,000  
                 
Total     482,630       760,416  
3. Purchase Accounting (Details) (USD $)
Sep. 30, 2017
Dec. 31, 2016
Assets acquired and liabilities assumed:
 
 
Goodwill
$ 7,647,266 
$ 272,315 
Acquisition Date
 
 
Consideration - issuance of securities and cash paid for fractional shares
7,007,069 
 
Assets acquired and liabilities assumed:
 
 
Cash
1,058,276 
 
Other assets
5,000 
 
Accrued liabilities
(1,431,158)
 
Goodwill
7,374,951 
 
Total purchase price
$ 7,007,069 
 
3. Purchase Accounting (Details 1) (USD $)
3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Purchase Accounting Details 1
 
 
 
 
Net loss
$ (3,478,025)
$ (1,885,198)
$ (9,980,370)
$ (4,564,423)
Net loss per share - basic and diluted
$ (1.09)
$ (0.77)
$ (3.69)
$ (1.86)
4. Property and Equipment (Details) (USD $)
Sep. 30, 2017
Dec. 31, 2016
Property and equipment, net
$ 5,062 
$ 6,217 
Computer hardware and software
 
 
Property and equipment, gross
10,706 
10,862 
Accumulated depreciation
(5,645)
(4,645)
Property and equipment, net
$ 5,062 
$ 6,217 
5. Accrued Expenses (Details) (USD $)
Sep. 30, 2017
Dec. 31, 2016
Accrued expenses
$ 1,711,300 
$ 438,028 
Legal
 
 
Accrued expenses
317,567 
21,477 
Pre-commercial costs
 
 
Accrued expenses
94,169 
Consulting
 
 
Accrued expenses
92,437 
13,105 
Audit and tax
 
 
Accrued expenses
893,949 
39,820 
License fees
 
 
Accrued expenses
205,444 
Contract manufacturing
 
 
Accrued expenses
35,657 
126,700 
Contract research
 
 
Accrued expenses
28,811 
16,800 
Miscellaneous expenses
 
 
Accrued expenses
$ 1,711,300 
$ 14,682 
6. Convertible Notes Payable (Details Narrative) (USD $)
3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Convertible Notes Payable Details Narrative
 
 
 
 
Interest expense
$ 120,229 
$ 0 
$ 242,982 
$ 0 
Amortization of financing costs
$ 68,530 
 
$ 68,530 
 
8. Stockholders' Equity (Details) (USD $)
9 Months Ended
Sep. 30, 2017
Options
 
Number of Shares, Outstanding at beginning of period
122,000 
Options, Granted
48,625 
Options, Exercised
Options, Forfeited and canceled
(5,625)
Number of Shares, Outstanding at end of period
165,000 
Number of Shares, Exercisable at end of period
123,562 
Weighted Average Exercise Price, Options
 
Weighted average exercise price, Outstanding at beginning of period
$ 2.55 
Weighted average exercise price options, Granted
$ 7.21 
Weighted average exercise price options, Exercised
$ 0.00 
Weighted average exercise price options, Forfeited and canceled
$ 2.55 
Weighted average exercise price, Outstanding at end of period
$ 3.92 
Weighted average exercise price, Exercisable at end of period
$ 3.47 
Weighted Average Remaining Contract Term, Options
 
Weighted Average Remaining Contract Term, Outstanding at end of period
7 years 6 months 14 days 
Weighted Average Remaining Contract Term, Exercisable
8 years 5 months 16 days 
8. Stockholders' Equity (Details 1) (Warrants, USD $)
9 Months Ended
Sep. 30, 2017
Warrants
 
Class of Warrant or Right [Line Items]
 
Number of Shares, Outstanding at beginning of period
Warrants, Assumed
317,630 
Number of Shares, Outstanding at end of period
317,630 
Number of Shares, Exercisable at end of period
317,630 
Weighted Average Exercise Price, Warrants
 
Weighted average exercise price, Outstanding at beginning of period
$ 0.00 
Weighted average exercise price warrants, Assumed
$ 123.61 
Weighted average exercise price, Outstanding at end of period
$ 123.61 
Weighted average exercise price, Exercisable at end of period
$ 123.61 
Weighted Average Remaining Contract Term, Warrants
 
Weighted Average Remaining Contract Term, Assumed
6 months 14 days 
Weighted Average Remaining Contract Term, Outstanding at end of period
6 months 14 days 
Weighted Average Remaining Contract Term, Exercisable
6 months 14 days 
Intrinsic Value, Warrants
 
Aggregate Intrinsic Value, Assumed
$ 0 
Aggregate Intrinsic Value, Outstanding at end of period
Exercisable Aggregate Intrinsic Value
$ 0 
8. Stockholders' Equity (Details Narrative) (USD $)
Sep. 30, 2017
Stockholders Equity Details Narrative
 
Unamortized stock-based compensation expense
$ 99,600 
9. Net Loss Per Share (Details)
9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Common stock dilutive securities
482,630 
760,416 
Convertible redeemable preferred stock
 
 
Common stock dilutive securities
638,416 
Warrants
 
 
Common stock dilutive securities
317,630 
Options to purchase common stock
 
 
Common stock dilutive securities
165,000 
122,000